Data from the JAK-pot collaboration of registries show that cycling JAKinibs and switching to a bDMARD appear to have similar effectiveness, after failing the first JAKinib.

June 2022

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.